BofA analyst Michael Ryskin raised the firm’s price target on 10x Genomics (TXG) to $18 from $15 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $22 from $17 at Barclays
- 10x Genomics downgraded to Neutral from Buy at Citi
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- 10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley
- 10x Genomics downgraded to Equal Weight from Overweight at Morgan Stanley